Diversity and Impacts of Mining on the Non-Volant Small Mammal Communities of Two Vegetation Types in the Brazilian Amazon

The CarajaÂs National Forest contains some of the largest iron ore deposits in the world. The majority of the minerals are found below a plant community known as Savana Metalo fila, or ªCangaº, which represents only 3% of the landscape within the CarajaÂs National Forest (CNF). The aim of our study was to understand the diversity of community of non-volant small mammals in the two predominant vegetation types: Ombrophilous Forest and Canga, and to examine how mining impacts these communities. Sampling was conducted from January 2010 to August 2011 in 11 sampling sites divided by the total area of Canga and 12 sampling sites in the forest, totalizing 23 sites. Of these, 12 sites (Canga and Forest) were considered impacted areas located close to the mine (\u3c\u3c 900 meters) and 11 sites (Canga and Forest), serving as controls, which were at least 7,000 meters from the mine. We recorded 28 species, 11 from the Order Didelphimorphia and 17 from the Order Rodentia. The two forest types shared 68.42% of the species found in the CNF. A gradient analysis (Non-metric multidimensional scaling) revealed that the first axis clearly separated the nonflying small mammal communities by vegetation type. Occupancy models showed that the detectability of species was affected by the distance from the mining activities. Of all the small mammals analyzed, 10 species were positively affected by the distance from mining in areas impacted (e.g. more likely to be detected farther from mining areas) and detectability was lower in impacted areas. However, three species were negatively affected by the distance from mining, with higher detectability in the impacted areas, and seven species showed no effect of their proximity to mining operations. To date, there are no studies in Brazil about the impact of mining on mammals or other vertebrates. This study reveals that the effect of mining may go beyond the forest destruction caused by the opening of the mining pits, but also may negatively affect sensitive wildlife species. Supplemental File 01 is attached below, in pdf and original docx file formats

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients